Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

EYLEA for Choroidal neovascularisation: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 7 adverse event reports in the FDA FAERS database where EYLEA was used for Choroidal neovascularisation.

Most Reported Side Effects for EYLEA

Side Effect Reports % Deaths Hosp.
Death 195 48.0% 190 0
Visual acuity reduced 31 7.6% 0 5
Retinal haemorrhage 25 6.2% 0 4
Blindness 20 4.9% 0 1
Eye pain 15 3.7% 0 3
Blindness transient 13 3.2% 0 2
Endophthalmitis 13 3.2% 0 3
Inappropriate schedule of drug administration 13 3.2% 0 4
Vision blurred 12 3.0% 0 1
Drug ineffective 11 2.7% 0 1
Uveitis 11 2.7% 0 0
Visual impairment 11 2.7% 0 1
Ocular hyperaemia 8 2.0% 0 2
Vitreous haemorrhage 8 2.0% 0 1
Blood pressure increased 7 1.7% 2 3

Other Indications for EYLEA

Age-related macular degeneration (156) Product used for unknown indication (22) Retinal vein occlusion (7) Macular degeneration (6)

Other Drugs Used for Choroidal neovascularisation

AFLIBERCEPT (2,953) RANIBIZUMAB (1,364) FARICIMAB\FARICIMAB-SVOA (306) BEVACIZUMAB (302) BROLUCIZUMAB-DBLL (104) BROLUCIZUMAB (102) FARICIMAB-SVOA (65) VERTEPORFIN (42) AVASTIN (12) LUCENTIS (11)

Related Pages

EYLEA Full Profile All Choroidal neovascularisation Drugs EYLEA Demographics EYLEA Timeline